克拉瓦塔受体之间的对抗性相互作用塑造了玉米耳朵的发展.
Penelope L Lindsay1,2, Fang Xu1, Lei Liu1
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11724, USA.
The New phytologist
|January 26, 2026
概括
玉米水晶系统的维护涉及FASCIATED EAR 3 (FEA3) 蛋白质,该蛋白质与几乎没有任何水晶系统1D (BAM1D) 相互作用. 它们在花大小中的对抗作用揭示了复杂的CLAVATA信号相互作用.
科学领域:
- 植物生物学 植物生物学
- 分子遗传学 分子遗传学
- 发育生物学是发展生物学.
背景情况:
- 梅里系统活动由CLAVATA (CLV) 信号通路调节,涉及富含白的重复受体 (LRR) 和CLV-EMBRYO SURROUNDING REGION (CLE) .
- FASCIATED EAR 3 (FEA3) 是一种类似LRR受体的蛋白质,对于玉米的水系维护至关重要,并且独立于正规CLV受体而起作用.
研究的目的:
- 为了阐明FEA3在玉米的相互作用网络.
- 识别CLV信号通路的新组件,并了解它们在美里系统调节中的作用.
主要方法:
- 使用基于TurboID的近距离标记在Zea的可能更多的系统来识别FEA3的交互伙伴.
- 进行了基因分析,以确定FEA3和几乎没有任何MERISTEM 1D (BAM1D) 之间的表位和对抗性关系.
主要成果:
- 鉴定了几乎没有任何的MERISTEM 1D (BAM1D) 作为与FEA3.3相互作用的假定共同受体.
- 在FEA3和BAM1D近距离标记蛋白质中发现了40多种共享蛋白质,这表明它们在一个共同的信号通路上趋同.
- FEA3和BAM1D在花花系统大小控制中表现出对抗性的作用,fea3突变体表现出更大的花花系统,bam1d突变体表现出更小的花花系统.
结论:
- 在体内基于TurboID的近距离标签有效地澄清了CLV信号通路中的复杂遗传相互作用.
- FEA3和BAM1D在物理上相互作用,并对抗性地调节玉米花朵花大小.
- 多个部分重叠的CLV受体综合体协调了meristem维护,扩大了下游信号组件的知识.
相关概念视频
Drug-Receptor Interaction: Antagonist
5.0K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.0K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.7K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.7K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.2K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.2K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.3K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.3K
Drug-Receptor Interactions
7.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.4K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.5K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.5K


